High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy

Neurology

Volumn 40, Issue 2, 1990, Pages 212-214

  Cook, D ^a   Dalakas, Marinos ^b   Galdi, A ^a   Biondi, D ^a   Porter, H ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN M;

AGED; ARTICLE; CASE REPORT; DEMYELINATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; NEUROPATHY; PRIORITY JOURNAL;

AGED; CASE REPORT; DEMYELINATING DISEASES; HUMAN; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; INFUSIONS, INTRAVENOUS; MALE; PARAPROTEINEMIAS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 0025355026     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.40.2.212     Document Type: Article

References (19)

1. Kelly JJ Jr. Peripheral neuropathies associated with monoclonal proteins; a clinical review. Muscle Nerve 1985;8:138–150.
2. Dalakas MC, Engel WK. Polyneuropathy with monoclonal gam-mopathy; studies of 11 patients. Ann Neurol 1981;10:45–52.
3. Dalakas MC. Ataxia and paraproteinemic polyneuropathy. Ann Neurol 1987;22:94–95.
4. Ilyas AA, Quarles RH, Dalakas MC, Brady RO. Polyneuropathy with monoclonal gammopathy: glycolipids are frequently antigens for IgM paraproteins. Proc -Natl Acad Sci USA 1985;82:6697–6700.
5. O’Shannessy DJ, Ilyas AA, Dalakas MC, Mendel JR, Quarles RH. Specificity of human IgM monoclonal antibodies from patients with peripheral neuropathy. J Neuroimmunol 1986;11:131–136.
6. Nobile-Orazio E, Hays AP, Latov N, et al. Specificity of mouse and human monoclonal antibodies to myelin associated glycopro-tein. Neurology 1984;34:1336–1342.
7. Gajdos PH, Outin H, Elkharrat D, et al. High-dose intravenous gamma globulin for myasthenia gravis. Lancet 1984;1:406.
8. Fateh-Moghadam A, Wick M, Bresinger U, et al. High-dose intravenous gamma globulin for myasthenia gravis. Lancet 1984;1:848.
9. Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gamma globulin for Kawasaki disease. Lancet 1984;2:1055–1058.
10. Faed JM, Day B, Pollock M, Taylor PK, Nukada H, Hammond-Tooke GD. High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Neurology 1989;39:422–425.
11. van Doorn PA, Brand A, Strengers PFW, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo controlled, crossover study. Neurology 1990;40:209–212.
12. Roifman CM, Schaffer FM, Wachsmuth SE, Murphy G, Gelfand EW. Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA 1987;258:513–515.
13. Medical Research Council. Aids to the investigation of peripheral nerve injuries. War memorandum, No. 45. London: Her Majesty’s Stationary Office, 1982.
14. Dalakas MC, Engel WK. Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol 1981;9(suppl):134–145.
15. Dwyer JM. Intravenous therapy with gamma globulin. Adv Intern Med 1987;32:111–136.
16. Imbach P, d’Appuzo V, Hirt A, et al. High-dose intravenous gamma globulin for idiopathic thrombocytopenic purpura in children. Lancet 1981;1:1228–1231.
17. Englehard D, Warner JL, Kapoor N, Good RA. Effect of intravenous immune globulin on natural killer cell activity: possible association with antiimmune neutropenia and idiopathic throm-bocytopenia. J Pediatr 1986;108:77–81.
18. McGarry RC, Helfand SL, Quarles RH, Roder JC. Recognition of myelin associated glycoprotein by the monoclonal antibody HNK-1. Nature 1983;306:376–378.
19. Zanetti M. Idiotypic regulation of autoantibody production. CRC Crit Rev Immunol 1986;6:151–183.